Generic drug of the therapeutic class: Allergology
active ingredients: Hydroxyzine
laboratory: Ucb Pharma SA
Divisible coated tablet
Box of 30
- Minor manifestations of anxiety.
- Premedication to general anesthesia.
- Symptomatic treatment of urticaria.
Dosage ATARAX 100 mg scored film tablet Box of 30
RESERVED FOR THE ADULT.
- Adult :
. Minor manifestations of anxiety : the average dose is 50 to 100 mg per day, up to 300 mg per day.
. Urticaria : the average dose is 50 to 100 mg daily.
. Premedication to general anesthesia : 100 to 200 mg in adults.
These doses can be reduced by half when only a momentary effect is desired.
- Elderly, severe hepatic or renal insufficiency: it is recommended to reduce the dosage by half.
- The treatment will be short-lived.
- Known hypersensitivity to one of the constituents of the drug, to one of its metabolites, to another derivative of piperazine, to aminophylline, or to ethylene diamine.
- Related to the anticholinergic effect :
. risk of glaucoma by closing the angle,
. risk of urinary retention related to a urethroprostatic disorder.
- Due to the presence of lactose, this drug is contraindicated in case of congenital galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency.
NOT RECOMMENDED :
- The administration of Atarax is not recommended in patients with cognitive or confounding disorders, because of the risk of aggravation related to the pharmacodynamic properties of the product.
- Breast-feeding: In the absence of data on the passage of hydroxyzine in breast milk, and given the sedative and atropine properties of this substance, breastfeeding is not recommended during treatment with hydroxyzine.
- Patients should be advised against the absorption of alcoholic beverages during treatment.
Atarax side effects
The adverse effects of Atarax are mainly related to its action on the central nervous system, its anticholinergic effects and the hypersensitivity reactions it can cause.
In placebo-controlled studies, the adverse events, regardless of their attributions, which were ≥ 1% during oral treatment with hydroxyzine were as follows:
Hydroxyzine (N = 735) / placebo (N = 630) .
. Drowsiness: 13.7% / 2.7%.
. Headache: 1.6% / 1.9%.
. Fatigue: 1.4% / 0.6%.
. Oral dryness: 1.2% / 0.6%.
Adverse effects reported since marketing are:
- Skin reactions:
erythema, pruritus, eczema; very rarely fixed pigmented erythema.
- Allergic manifestations:
urticaria; more rarely bronchospasm, angioedema, anaphylactoid reaction.
- Psychiatric effects:
confusion, more rarely excitation, hallucinations, disorientation, insomnia.
- Neurological effects:
drowsiness, more rarely convulsions, dyskinesias, tremor, vertigo.
- Ophthalmological effects:
disturbances of accommodation.
- Cardiovascular effects:
- Gastrointestinal effects:
dry mouth, constipation.
- Urological effects: